Cell-free DNA diagnostics · Molecular residual disease · NASDAQ — Quick Take
Healthcare was the #1 sector in the Wed 23 Sep US VolumeSurge — 13 of 50 passing names versus 12 Technology and 12 Basic Materials (the HK screen passed zero names, so there was no Hong Kong signal to work from). Natera was the largest name in that healthcare cluster not already covered: #6 by turnover, +5.5% to $390.90 on 1.5M shares / $594M turnover, behind only SNDK, MRNA and SHOP — all of which have been covered in the past six weeks. The catalyst is specific and dated: on 22 Sep, Japan's PMDA approved Signatera as a companion diagnostic (CDx) in muscle-invasive bladder cancer (MIBC), to guide adjuvant atezolizumab (Roche's Tecentriq) decisions, on the back of the Phase 3 IMvigor011 trial run at 20+ Japanese sites. It follows FDA approval in MIBC and PMDA approval in colorectal cancer — the third significant regulatory milestone in a matter of months — with a supportive lung-cancer study landing in the same week. *Loss-making, so no meaningful forward P/E.
| Year | Revenue | Rev Growth | Op Margin | Net Income |
|---|---|---|---|---|
| FY2022 | $820M | +31% | ~−67% | −$548M |
| FY2023 | $1,082M | +32% | ~−43% | −$435M |
| FY2024 | $1,697M | +56.8% | −13.1% | −$190M |
| FY2025 | $2,306M | +35.9% | −13.4% | −$208M |
| Q2 2026 | $753M | +37.7% | −10.1% | −$67M |
Gross margin: 60.3% (FY2024) → 64.7% (FY2025) → 64.5% (Q2 2026). Cash and equivalents $1,091.5M at 30 Jun 2026 against $80.3M of debt; FY2025 produced a positive cash inflow of $107.6M. FY2022–23 operating margins are approximate (derived from reported revenue and net loss; those years carried outsized legal and litigation expense). FY2026 guidance: revenue $2.85–2.91B, gross margin 64–66%, positive cash flow.
Natera is the best-run pure-play in liquid biopsy: the volume data, the margin progression and the run of CDx approvals all say the technology is crossing from promising to reimbursed, and Japan MIBC extends a moat built on trial-level evidence rather than marketing. The problem is that the stock trades at about 20x sales and a new 52-week high with the average sell-side target below the last print, so you are buying a fully-priced execution story where the accrual true-ups and 20%+ opex growth are the tripwires. The trigger here is genuinely incremental but small in yen terms — worth owning on weakness, not worth chasing a $390 tape after a regulatory headline.
Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers.